CAR-T cell manufacturing: Major process parameters and next-generation strategies.
J Exp Med
; 221(2)2024 Feb 05.
Article
en En
| MEDLINE
| ID: mdl-38226974
ABSTRACT
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Enfermedades Autoinmunes
Límite:
Humans
Idioma:
En
Revista:
J Exp Med
/
J. exp. med
/
Journal of experimental medicine
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos